Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400834 | 1.00 | CASP3 (0.57) | CASP3KMT2ACTRB1MDM4TP53 | |
| SCHEMBL3207886 | 1.00 | CASP3 (0.57) | CASP3KMT2ACTRB1MDM4TP53 | |
| SCHEMBL119383 | 1.00 | CASP3 (0.57) | CASP3KMT2ACTRB1MDM4TP53 | |
| SCHEMBL33377860 | 1.00 | CASP3 (0.57) | CASP3KMT2ACTRB1MDM4TP53 | |
| SCHEMBL12475809 | 0.92 | CASP3 (0.53) | CASP3KMT2AMDM4TP53MME | |
| SCHEMBL16397970 | 0.92 | CASP3 (0.53) | CASP3KMT2AMDM4TP53MME | |
| SCHEMBL30191600 | 0.92 | CASP3 (0.53) | CASP3KMT2AMDM4TP53MME | |
| SCHEMBL12475805 | 0.92 | CASP3 (0.53) | CASP3KMT2AMDM4TP53MME | |
| SCHEMBL22960738 | 0.92 | CASP3 (0.53) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL15674221 | 0.92 | CASP3 (0.53) | CASP3KMT2AMDM4TP53MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110312730-B | Cytotoxins and conjugates, uses thereof and methods of preparation | 四川科伦博泰生物医药股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-116446054-A | CBP/P300 inhibitor, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-07-18 | — | — | CN | disclosed |
| US-11207420-B2 | Cytotoxin and conjugate, uses of same and preparation method therefor | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-12-28 | — | — | US | disclosed |
| CN-106117310-B | Small molecule conjugates for intracellular delivery of biologically active compounds | 弗·哈夫曼-拉罗切有限公司 | 2021-04-06 | — | — | CN | disclosed |
| US-20200179529-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME AND PREPARATION METHOD THEREFOR | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-06-11 | — | — | US | disclosed |
| EP-3617221-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME, AND PREPARATION METHOD THEREFOR | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-03-04 | — | — | EP | disclosed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-9968647-B2 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2018-05-15 | — | — | US | disclosed |
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | disclosed |
| EP-3147367-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| WO-2012089602-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | disclosed |
| WO-2012089352-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| EP-2350031-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | Ensemble Therapeutics Corporation (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| WO-2010022249-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE DISCOVERY CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| CN-101511783-A | N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions | NOVARTIS AG (CH) | 2009-08-19 | — | — | CN | disclosed |
| EP-1985612-A1 | Arymethylen substituted N-Acyl-gamma-aminoalcohols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11207420-B2 | Cytotoxin and conjugate, uses of same and preparation method therefor | CD2, HAVCR2, CD4 | CASP3 2049/4885KMT2A 4202/4885CTRB1 1573/4885 |
| US-20200179529-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME AND PREPARATION METHOD THEREFOR | CD2, HAVCR2, CD4 | CASP3 2049/4885KMT2A 4202/4885CTRB1 1573/4885 |
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | UGT2B7, CYP3A7, STS | CASP3 104/4885KMT2A 2404/4885CTRB1 2309/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | CASP3 635/4885KMT2A 4608/4885CTRB1 6/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | CASP3 549/4885KMT2A 4176/4885CTRB1 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.